EUVIMEDEUVIMED entdecken
Crossref

Rosavin ameliorates alcoholic fatty liver disease through PPARG-dependent inhibition of the p38 MAPK and IGF-1 pathways

Shen Wang, Jinhui Cai, Ziqing Tang, Shurong Chen, Huike Chen, Yunjuan Tan, Ruirui Huang, Minhua Wu, Yanxia Wu, Xiaoxia Ye

Biochemical Pharmacology · 2026-09 · 251 · 118148

DOI: 10.1016/j.bcp.2026.118148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Shen Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Guangdong Medical University, Zhanjiang, Guangdong 524023, China. Hauptthemen laut MEDLINE: PPAR gamma, Insulin-Like Growth Factor I, p38 Mitogen-Activated Protein Kinases, Fatty Liver, Alcoholic. Die Arbeit nennt 59 Literaturangaben. Gefördert von: National College Students Innovation and Entrepreneurship Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rosavin, a characteristic component of Rhodiola rosea L., exhibits various pharmacological activities, including antioxidant and anti-inflammatory effects. However, its role in alcoholic fatty liver disease (AFLD) remains unclear. The aim of this study was to investigate the protective effects of Rosavin against AFLD and to elucidate its underlying molecular mechanisms. In this study, Rosavin (25 μM and 50 μM for in vitro; 100 and 200 mg/kg/d via oral gavage for 10 days in vivo) was found to significantly mitigate alcohol-induced hepatic lipid accumulation, enhance antioxidant capacity, and alleviate liver injury, demonstrating its protective effects against AFLD both in vitro and in vivo. Through network pharmacology and molecular docking, six potential targets of Rosavin in AFLD were identified: nitric oxide synthase 3 (NOS3), proto-oncogene tyrosine-protein kinase Src (SRC), peroxisome proliferator-activated receptor gamma (PPARG), mitogen-activated protein kinase 14 (MAPK14, also known as p38α), tumor necrosis factor alpha (TNFα), and insulin-like growth factor 1 (IGF-1). RT-qPCR and western blotting confirmed that Rosavin downregulates PPARG, TNFα, and IGF-1 expression and suppresses p38 phosphorylation. Rescue experiments further revealed that the suppressive effect of Rosavin on PPARG expression is reversed by the PPARG-specific agonist Mesalazine, which not only counteracts the protective effects of Rosavin but also reverses Rosavin-induced changes in MAPK14 and IGF-1 expression. In conclusion, Rosavin alleviates AFLD by downregulating PPARG and subsequently modulating the MAPK14 and IGF-1 signaling pathways. This study provides the first evidence that Rosavin protects against AFLD via PPARG, highlighting its potential as a therapeutic agent for AFLD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR gammaInsulin-Like Growth Factor Ip38 Mitogen-Activated Protein KinasesFatty Liver, AlcoholicAnimalsMaleMiceMice, Inbred C57BLHumansSignal TransductionPPAR-gamma AgonistsMAP Kinase Signaling System

Stichwörter der Autor:innen

Alcoholic fatty liver diseaseIGF-1PPARGRosavinp38 MAPK

Substanzen

PPAR gammaInsulin-Like Growth Factor Ip38 Mitogen-Activated Protein KinasesPparg protein, mousePPAR-gamma Agonists

Autor:innen und Institutionen

  • School of Pharmacy, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
  • The First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
  • School of Obstetrics and Pediatrics, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
  • School of Basic Medical Sciences, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
  • Pathological Diagnosis and Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524023, China. Electronic address: wuyanxia2005@126.com.
  • School of Basic Medical Sciences, Guangdong Medical University, Zhanjiang, Guangdong 524023, China; Pathological Diagnosis and Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 5…

Förderung

  • National College Students Innovation and Entrepreneurship Training Program

Zitieren

APA

Wang, S., Cai, J., Tang, Z., Chen, S., Chen, H., Tan, Y., Huang, R., Wu, M., Wu, Y., & Ye, X. (2026). Rosavin ameliorates alcoholic fatty liver disease through PPARG-dependent inhibition of the p38 MAPK and IGF-1 pathways. Biochemical Pharmacology, 251, 118148. https://doi.org/10.1016/j.bcp.2026.118148

Vancouver

Wang S, Cai J, Tang Z, Chen S, Chen H, Tan Y, et al. Rosavin ameliorates alcoholic fatty liver disease through PPARG-dependent inhibition of the p38 MAPK and IGF-1 pathways. Biochemical Pharmacology. 2026;251:118148. doi:10.1016/j.bcp.2026.118148

BibTeX
@article{Wang2026,
  author = {Wang, Shen and Cai, Jinhui and Tang, Ziqing and Chen, Shurong and Chen, Huike and Tan, Yunjuan and Huang, Ruirui and Wu, Minhua and Wu, Yanxia and Ye, Xiaoxia},
  title = {Rosavin ameliorates alcoholic fatty liver disease through PPARG-dependent inhibition of the p38 MAPK and IGF-1 pathways},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {251},
  pages = {118148},
  doi = {10.1016/j.bcp.2026.118148}
}
Kostenlos starten →